These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 17471434

  • 1. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis.
    Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, Flynn JL.
    J Infect Dis; 2007 Jun 01; 195(11):1643-50. PubMed ID: 17471434
    [Abstract] [Full Text] [Related]

  • 2. Why does tumor necrosis factor targeted therapy reactivate tuberculosis?
    Ehlers S.
    J Rheumatol Suppl; 2005 Mar 01; 74():35-9. PubMed ID: 15742463
    [Abstract] [Full Text] [Related]

  • 3. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins.
    Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M.
    Eur J Immunol; 1994 Sep 01; 24(9):2040-8. PubMed ID: 8088324
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
    Haak-Frendscho M, Marsters SA, Mordenti J, Brady S, Gillett NA, Chen SA, Ashkenazi A.
    J Immunol; 1994 Feb 01; 152(3):1347-53. PubMed ID: 8301136
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence.
    Dambuza I, Allie N, Fick L, Johnston N, Fremond C, Mitchell J, Quesniaux VF, Ryffel B, Jacobs M.
    Tuberculosis (Edinb); 2008 May 01; 88(3):221-34. PubMed ID: 17950671
    [Abstract] [Full Text] [Related]

  • 6. Reactivation of tuberculosis by tumor necrosis factor neutralization.
    Jacobs M, Samarina A, Grivennikov S, Botha T, Allie N, Fremond C, Togbe D, Vasseur V, Rose S, Erard F, Monteiro A, Quesniaux V, Ryffel B.
    Eur Cytokine Netw; 2007 Mar 01; 18(1):5-13. PubMed ID: 17400533
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha).
    McLaughlin PJ, Elwood NJ, Russell SM, Andrew SM, McKenzie IF.
    Anticancer Res; 1992 Mar 01; 12(4):1243-6. PubMed ID: 1503416
    [Abstract] [Full Text] [Related]

  • 9. Recombinant human soluble tumor necrosis factor-alpha receptor fusion protein partly attenuates ventilator-induced lung injury.
    Wolthuis EK, Vlaar AP, Choi G, Roelofs JJ, Haitsma JJ, van der Poll T, Juffermans NP, Zweers MM, Schultz MJ.
    Shock; 2009 Mar 01; 31(3):262-6. PubMed ID: 18650784
    [Abstract] [Full Text] [Related]

  • 10. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB, Bond MI.
    Semin Arthritis Rheum; 2008 Dec 01; 38(3):208-17. PubMed ID: 18221983
    [Abstract] [Full Text] [Related]

  • 11. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
    Lee JH, Cho JH, Yeo J, Lee SH, Yang SH, Sung YC, Kang JH, Park CS.
    Biologicals; 2013 Mar 01; 41(2):77-83. PubMed ID: 23190454
    [Abstract] [Full Text] [Related]

  • 12. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab.
    Wallis RS, Ehlers S.
    Semin Arthritis Rheum; 2005 Apr 01; 34(5 Suppl1):34-8. PubMed ID: 15852254
    [Abstract] [Full Text] [Related]

  • 13. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade.
    Wallis RS.
    Arthritis Rheum; 2008 Apr 01; 58(4):947-52. PubMed ID: 18383389
    [Abstract] [Full Text] [Related]

  • 14. TNF-alpha blockade and tuberculosis: better look before you leap.
    Arend SM, Breedveld FC, van Dissel JT.
    Neth J Med; 2003 Apr 01; 61(4):111-9. PubMed ID: 12852719
    [Abstract] [Full Text] [Related]

  • 15. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?
    Ehlers S.
    Clin Infect Dis; 2005 Aug 01; 41 Suppl 3():S199-203. PubMed ID: 15983900
    [Abstract] [Full Text] [Related]

  • 16. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.
    Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel M, Scheurich P, Pfizenmaier K.
    J Immunother; 2008 Apr 01; 31(3):225-34. PubMed ID: 18317365
    [Abstract] [Full Text] [Related]

  • 17. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.
    Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL.
    Arthritis Rheum; 2007 Aug 01; 56(8):2557-65. PubMed ID: 17665452
    [Abstract] [Full Text] [Related]

  • 18. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS.
    J Infect Dis; 2006 Aug 15; 194(4):486-92. PubMed ID: 16845632
    [Abstract] [Full Text] [Related]

  • 19. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
    Vossen AC, Tibbe GJ, Buurman WA, Benner R, Savelkoul HF.
    Eur Cytokine Netw; 1996 Dec 15; 7(4):751-5. PubMed ID: 9010677
    [Abstract] [Full Text] [Related]

  • 20. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies.
    Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E.
    Am J Physiol Gastrointest Liver Physiol; 2008 Apr 15; 294(4):G938-47. PubMed ID: 18258792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.